Want to see FR:ALTHX full AI Analyst Report?
Top Page
Theranexus SA
(ALTHX)
Select Model
Select Model
Rating:44Neutral
Price Target:
€3.00
▼(-24.43% Downside)
Action:Reiterated
Date:09/10/26
The score is primarily weighed down by weak financial performance—ongoing losses, sustained cash burn, and the 2025 revenue drop to zero—creating elevated funding and execution risk. Technicals add further pressure with a bearish trend and negative MACD, partially offset by oversold readings (RSI/Stochastic). Valuation provides limited support because the negative P/E is not informative for a loss-making business and there is no dividend yield.
Positive Factors
Moderated Debt
Debt has moderated from prior peaks and remained around €2.9m recently, which somewhat reduces leverage pressure compared with earlier periods. This improvement does not remove balance-sheet risk, but it may provide modestly greater financial flexibility while the company advances its clinical pipeline.
Negative Factors
Zero Revenue
The complete revenue drop to zero in 2025 highlights substantial commercialization and execution risk for a clinical-stage company. Without recurring product revenue, Theranexus has limited internal funding capacity and remains dependent on successfully advancing programs or securing external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Moderated Debt
Debt has moderated from prior peaks and remained around €2.9m recently, which somewhat reduces leverage pressure compared with earlier periods. This improvement does not remove balance-sheet risk, but it may provide modestly greater financial flexibility while the company advances its clinical pipeline.
Read all positive factors
Theranexus SA (ALTHX) vs. iShares MSCI France ETF (EWQ)
Market Cap
€47.21M
Dividend YieldN/A
Average Volume (3M)53.88K
Price to Earnings (P/E)―
Beta (1Y)0.26
Revenue GrowthN/A
EPS Growth54.40%
CountryFR
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.10
Shares Outstanding14,472,778
10 Day Avg. Volume32,559
30 Day Avg. Volume53,883
Financial Highlights & Ratios
PEG Ratio-2.04
Price to Book (P/B)14.83
Price to Sales (P/S)0.00
P/FCF Ratio-31.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.79
Revenue Forecast (FY)N/A
Theranexus SA Business Overview & Revenue Model
Company Description
Theranexus, a biopharmaceutical enterprise, specializes in the creation of potential medications for ailments affecting the central nervous system. Their primary investigational compound, THN102, is presently undergoing Phase II clinical evaluatio...
How the Company Makes Money
Theranexus is a clinical-stage biopharmaceutical company; detailed, consistently disclosed product-sales revenue information is not available here, and the company is not generally expected to generate meaningful recurring revenue from commercial ...
Theranexus SA Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.24M | 0.00 | 2.28M | 296.33K | 414.90K | 602.00 |
| Gross Profit | -60.60K | -108.60K | -333.55K | -4.64M | 82.90K | -8.82M |
| EBITDA | -9.76M | -10.12M | -2.53M | -7.39M | -5.93M | -8.67M |
| Net Income | -2.03M | -3.00M | -1.77M | -6.83M | -6.57M | -8.15M |
Balance Sheet | ||||||
| Total Assets | 22.63M | 10.54M | 3.74M | 7.24M | 12.05M | 16.89M |
| Cash, Cash Equivalents and Short-Term Investments | 17.45M | 7.77M | 966.59K | 4.90M | 9.11M | 12.53M |
| Total Debt | 2.59M | 2.88M | 2.87M | 3.64M | 4.89M | 5.33M |
| Total Liabilities | 19.66M | 7.64M | 5.40M | 5.02M | 6.33M | 6.71M |
| Stockholders Equity | 2.12M | 1.99M | -1.66M | 2.22M | 5.73M | 10.18M |
Cash Flow | ||||||
| Free Cash Flow | 8.86M | -939.81K | -3.40M | -6.40M | -5.41M | -6.40M |
| Operating Cash Flow | 9.07M | -883.76K | -3.37M | -6.36M | -5.37M | -6.25M |
| Investing Cash Flow | -319.59K | -168.23K | 77.04K | -61.11K | 323.53K | -150.62K |
| Financing Cash Flow | 7.74M | 7.85M | -646.42K | 2.22M | 1.63M | 7.71M |
Theranexus SA Technical Analysis
Positive
3.97
Price Trends
3.54
Negative
3.65
Negative
3.39
Negative
Market Momentum
-0.07
Negative
49.07
Neutral
58.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALTHX, the sentiment is Positive. The current price of 3.97 is above the 20-day moving average (MA) of 3.21, above the 50-day MA of 3.54, and above the 200-day MA of 3.39, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 49.07 is Neutral, neither overbought nor oversold. The STOCH value of 58.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALTHX.
Theranexus SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | €944.71M | -28.90 | ― | ― | -23.21% | -50.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | €17.92M | -1.00 | 52.39% | ― | -610.31% | 43.88% | |
45 Neutral | €86.92M | -2.03 | -54.15% | ― | ― | 6.26% | |
44 Neutral | €47.21M | -33.75 | -98.95% | ― | ― | 54.40% | |
41 Neutral | €51.16M | -6.58 | 27.28% | ― | 12.66% | 44.01% | |
21 Underperform | €10.87M | -0.76 | 148.60% | ― | -24.18% | -120.44% |
* Healthcare Sector Average
FR:ALTHX
Theranexus SA
3.27
1.45
79.77%
FR:SIGHT
GenSight Biologics SA
0.07
-0.05
-41.46%
FR:AB
AB Science SA
0.53
-0.66
-55.39%
FR:ALSEN
Sensorion SAS
8.60
-9.70
-53.01%
FR:ALINS
Intrasense SA
0.21
-0.06
-21.67%
FR:MEDCL
MedinCell SA
26.30
-10.02
-27.59%
Theranexus SA Corporate Events
THX Pharma Nears Break-Even as Rare Disease Pivot Gains Traction
Sep 29, 2026
THX Pharma reported a near break-even performance for the first half of 2026, underpinned by €3.24 million in revenue and a sharply reduced net loss of €0.1 million compared with €1.07 million a year earlier. The improvement stem...
THX Pharma Secures Long-Term European Patent Protection for Batten-1
Sep 9, 2026
THX Pharma and the Beyond Batten Disease Foundation have secured a key European patent protecting the use of miglustat, the active ingredient in Batten-1, for treating juvenile Batten disease. Jointly owned by BBDF, Baylor College of Medicine and ...
THX Pharma Advances Batten-1 With Global Phase 3 Trial Filings for Juvenile Batten Disease
Sep 1, 2026
THX Pharma (Theranexus), together with Beyond Batten Disease Foundation and Biocodex, has submitted regulatory applications in the United States, United Kingdom and several European countries to launch an international phase 3 trial of Batten-1, a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.